Loading...
Osteonecrosis of the jaw associated with everolimus: A case report
Everolimus, a mammalian target of rapamycin inhibitor, has recently been approved for the treatment of metastatic estrogen receptor-positive breast cancer, at a daily dose of 10 mg in combination with exemestane. Osteonecrosis of the jaw (ONJ) is a rare but severe condition, characterized by exposed...
Na minha lista:
| Udgivet i: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
D.A. Spandidos
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5351763/ https://ncbi.nlm.nih.gov/pubmed/28357105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.1100 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|